Graves’ disease: a plain-language guide

trialport plain-language guide to Graves' Disease

Graves’ disease is an autoimmune condition in which the immune system makes an antibody that switches the thyroid gland on and keeps it on, so the gland makes far more thyroid hormone than the body needs [1].

This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.

Key facts

  • Graves’ disease is the most common cause of an overactive thyroid. About 4 in 5 people with an overactive thyroid in the United States and the United Kingdom have it [1,2].
  • It affects nearly 1 in 100 people in the United States, and is roughly 7 to 8 times more common in women than in men [1,3].
  • The usual symptoms are weight loss despite eating normally, a fast or irregular heartbeat, shaky hands, sweating, disliking heat, anxiety, poor sleep, and sometimes a swelling in the neck called a goiter [1,2].
  • About a third of people develop thyroid eye disease, which follows its own course and does not track the thyroid blood tests. Smoking makes it considerably worse [3,5].
  • Three main treatments exist, and each involves trade-offs: antithyroid tablets, radioactive iodine and surgery. Many people end up taking thyroid hormone replacement for life [1,4].
  • Thyroid storm, a sudden severe flare, is rare and is a medical emergency [9].

On this page

What is Graves’ disease?

The thyroid is a small butterfly-shaped gland at the front of the neck. It makes thyroid hormones, which set the speed at which the body uses energy [1,3].

Graves’ disease is autoimmune: the immune system, which normally attacks germs, targets the body’s own tissue by mistake. Here it makes an antibody, the TSH receptor antibody, that latches onto the switch on thyroid cells and holds it on, so the gland keeps making hormone whether or not the body needs it [1,3].

Too much thyroid hormone is called hyperthyroidism, an overactive thyroid, or thyrotoxicosis. Graves’ disease is the commonest cause, about 4 in 5 cases in the United States and the United Kingdom [1,2]. Other causes include thyroid lumps, temporary inflammation called thyroiditis, and some medicines [2,7]. Named after Robert Graves, an Irish doctor who described it in the nineteenth century, it differs from Hashimoto’s disease, where the thyroid ends up underactive [1,3].

How common is it?

Graves’ disease affects nearly 1 in 100 people in the United States [1]. European guidelines put the prevalence at 1 to 1.5 in 100, with about 3 in 100 women and 0.5 in 100 men developing it at some point in life, and 20 to 30 new cases a year per 100,000 people where diets contain enough iodine [4]. Prevalence counts everyone living with a condition at once; incidence counts new cases in a year. Women are affected about 7 to 8 times more often than men, and reported peak ages range from 20 to 60 [2,3,4].

Read these with care: most come from a few higher-income countries, and rates depend partly on iodine in the diet [4]. Comparable figures for Africa, South America, the Middle East and much of Asia were not available, and mild cases go unnoticed, so the real number is probably higher [7].

What causes it?

Nobody knows why the immune system turns on the thyroid. Genes and something in the environment appear to combine [1]. A gene is a set of instructions inside cells. No single gene causes it and it is not passed down in a simple pattern, though twin studies suggest about 80 percent of the susceptibility is genetic, and roughly 30 percent of people have a relative with Graves’ or Hashimoto’s disease [4].

Environmental contributors include cigarette smoking, a lot of iodine in the diet, major stress, and the months after a pregnancy [4]. Smoking counts most: it makes Graves’ disease more likely, lowers the chance of remission after tablets, and the British Thyroid Foundation puts the risk of thyroid eye disease in smokers at up to eight times that of non-smokers [4,7]. Nothing a person did caused it, though stopping smoking changes what follows [1,5].

What are the symptoms?

Symptoms come from the body running too fast, and can build slowly or arrive over a few weeks, subtle enough to go unnoticed [7]. Common ones are [1,2,7]:

  • weight loss, even while eating normally or more than usual
  • a fast, pounding or irregular heartbeat
  • feeling hot, sweating more, disliking warm weather
  • shaking hands, weak muscles, tiredness
  • nervousness, anxiety, mood swings, poor sleep
  • a swelling in the neck from an enlarged thyroid, called a goiter

Untreated, it can also cause an irregular heart rhythm and thinning bones [1,9].

Thyroid eye disease. This separate problem affects the tissue around the eyes and needs its own treatment [11]. About a third of people develop it, and around 5 in 100 have inflammation severe enough to threaten sight [3]. Symptoms include gritty or dry eyes, light sensitivity, puffy or pulled-back eyelids, bulging eyes and double vision [1,9]. Its severity is not related to the severity of the overactive thyroid, so normal blood tests do not mean the eyes are fine [3]. Smoking substantially worsens it and stopping helps [5]. Eye symptoms need an eye doctor as well as a hormone specialist [3].

When to seek urgent help. Thyroid storm is rare and is a medical emergency: a sudden severe flare, usually where an overactive thyroid is undiagnosed or poorly controlled. Warning signs are a very fast heartbeat, a high temperature, yellowing of the skin or eyes, severe agitation or confusion, and loss of consciousness. Call an ambulance straight away [9]. About 1 in 10 people who develop it die from it [4]. Anyone on carbimazole, methimazole or propylthiouracil who develops a sore throat, mouth ulcers, an unexplained fever or yellowing of the skin should also stop the tablets and get advice the same day [1,7].

How is it diagnosed?

A family doctor usually starts with a blood test, then refers most people to an endocrinologist, a hormone specialist [2,7]. TSH, the signal from the pituitary gland, is low, while free T4 and often T3, the thyroid hormones themselves, are high [3,7]. TSH receptor antibodies confirm Graves’ disease specifically, and a positive result usually means no further testing [3,4]. Otherwise a radioactive iodine uptake test and thyroid scan show whether the whole gland is overactive or only lumps within it [1]. Diagnosis is often delayed, since symptoms are easily put down to stress [7] and eye disease is often mistaken for other eye conditions [10].

How is it treated?

No treatment switches the antibody off, so treatment reduces how much hormone the thyroid makes. Three options exist, each with real trade-offs. A beta blocker such as propranolol usually comes first, settling a racing heart and tremor [1,2,4].

Antithyroid tablets. Carbimazole is the usual first choice in the UK, methimazole in the United States, and propylthiouracil where those are unsuitable [4,8]. A course lasts 12 to 18 months, usually by titration: starting higher and lowering the dose as levels settle. An alternative, block and replace, keeps a steady higher dose and adds levothyroxine, and was not shown to work better [4]. About 53 percent of people relapse afterward, far more than after radioactive iodine or surgery [4].

Radioactive iodine. A single drink or capsule of iodine-131 gradually destroys the hormone-making cells, and almost everyone eventually becomes underactive and needs levothyroxine for life [1,8]. It is not given in pregnancy or breastfeeding, and conception should wait at least 6 months [4,8]. It can worsen thyroid eye disease, which low-dose steroid tablets largely prevent, and is avoided in moderate-to-severe active eye disease [4,5].

Surgery. Removing the whole thyroid ends the overactivity permanently and does not appear to worsen eye disease. It is often chosen for a large goiter, severe disease or significant eye problems, with risks including damage to the nerve supplying the voice box and low calcium [4,8]. Levels are controlled with tablets first, and levothyroxine is needed for life afterward [1,4].

Treating the eyes. Mild disease is managed with artificial tears, sunglasses and a six-month selenium course [1,5]. Moderate-to-severe active disease is treated at a specialist thyroid-eye clinic. European guidelines place glucocorticoids given into a vein first; the joint American and European consensus statement places the infused medicine teprotumumab first for most people [6]. Teprotumumab was approved in the United States in January 2020, by the MHRA in May 2025 and in the European Union on 19 June 2025, the first such treatment in Europe [6,10,11,13]. Approval is not access: as of March 2026, NICE had not recommended it for NHS use in England [12]. It can cause permanent hearing loss, must not be used in pregnancy, and about 30 percent of people lose the improvement within a year [6,11].

Living with Graves’ disease

Most people are followed by an endocrinologist with regular blood tests, more often at first, and for life after radioactive iodine or surgery [7]. For anyone who smokes, stopping is the single most useful step, above all for the eyes [1,5]. Large amounts of iodine can worsen an overactive thyroid, so ask a doctor about seaweed, kelp and iodine supplements [1].

Pregnancy. Poorly controlled hyperthyroidism in pregnancy raises the risk of miscarriage, pre-eclampsia, early birth and low birth weight, and medicine choice differs by stage [9,14]. Methimazole and carbimazole risk birth defects around weeks 6 to 10, affecting 2 to 4 percent of exposed babies. Propylthiouracil carries a similar rate but a less severe pattern, so it is preferred when trying to conceive and through the first three months [4,14]. The 2018 European guideline advised switching back to methimazole after 16 weeks; the 2026 American guideline makes no specific recommendation on switching back, so this is a decision to make with a specialist [4,14]. Use contraception while taking carbimazole or within 6 months of radioactive iodine, and raise pregnancy plans before conceiving [9].

Anxiety, low mood and poor sleep are part of the condition, not a personal failing, and usually improve as levels settle [2]. Patient organizations offer peer support, which many people value highly [15].

Thinking about a clinical trial?

Clinical trials test whether a treatment works and is safe. Most current Graves’ disease research concerns thyroid eye disease. Deciding whether to look into a study is personal, and it helps to take it in steps.

1. Understand what the study is asking

Worth being clear on:

  • what researchers want to learn, and what is being studied against what
  • how long the study lasts, often six months or more
  • what visits, tests or procedures are involved, and whether travel to a specialist center is needed
  • the possible benefits, the known and unknown risks, and what happens when the study ends

2. Consider possible medical suitability

Every trial has rules about who can take part, called eligibility criteria: some describe who can join, others who cannot. For a Graves’ disease study they might include a confirmed diagnosis with positive TSH receptor antibodies, thyroid hormone levels within a set range, a score for how active the eye disease is, a minimum amount of eye bulging, no recent steroid treatment, and reliable contraception where a medicine could harm a developing baby.

trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.

Explore Graves’ disease clinical trials through trialport

3. Consider whether participation fits your life

Medical suitability is only part of it. A study can look right on paper and still be hard in practice:

  • the time each visit takes, how many there are, the travel involved and who would come along
  • work, school or caring responsibilities, and how much time off is realistic
  • support from family and friends
  • how you feel about infusions, daily tablets for months, or repeated eye examinations
  • whether you understand the study well enough to decide, and whether it feels right

trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.

4. Ask questions before deciding

Questions to put to a research team:

  • Why is this study being carried out, and what is already known?
  • What exactly would I need to do, and for how long?
  • What are the known risks, and what is still unknown?
  • Could I receive a placebo? A placebo is a dummy treatment with no active medicine, used so researchers can compare results fairly. Would I still receive my usual thyroid treatment alongside it?
  • Would my current tablets or treatment plans need to change?
  • What happens if I am planning a pregnancy, now or during the study?
  • Can I leave the study after joining, and what happens if I do?
  • Who provides my usual thyroid care, and who do I contact out of hours?

Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.

Search for clinical trials at app.trialport.com.

Current research

Most current work is on the eyes rather than the gland:

  • Blocking the IGF-1 receptor. Teprotumumab was the first medicine of this type [11]. A second, veligrotug, was approved in the United States on 26 June 2026 for thyroid eye disease whatever its activity or duration. It is not approved elsewhere as far as could be verified [16].
  • Other treatments for the eyes. Tocilizumab and rituximab are used in some centers, not as a first choice, and statins are being studied, since statin users appear less likely to develop eye disease [6].
  • Targeting the antibody itself. Antibodies, peptides and small molecules designed to block the thyroid switch are being studied, aiming to change the disease rather than only lower hormone output. This work is early [4].

Study status checked: 3 August 2026. Research moves quickly, so this list will date. For current information, search at app.trialport.com.

Support and further information

In the United States, the Graves’ Disease and Thyroid Foundation, founded in 1990 by someone living with the condition, runs a resource library and online support groups [15]. The American Thyroid Association publishes patient information and a specialist finder [3], and the NIDDK has a clear overview in English and Spanish [1].

In the United Kingdom, the British Thyroid Foundation produces free leaflets, including versions in Arabic, Polish, Urdu and Mandarin [7], and the Thyroid Eye Disease Charitable Trust covers the eye condition only [17]. In Australia, the Australian Thyroid Foundation provides education and support [18].

Coverage elsewhere is thin, and where no local group exists a national thyroid association or the treating clinic is the best starting point.

Well-known people

Gail Devers, the American sprinter who won three Olympic gold medals, has spoken publicly about living with Graves’ disease and symptoms of thyroid eye disease for more than thirty years, and about waiting over two years for answers [19].

Assumptions about someone’s diagnosis are often wrong, so this page names only people who have described the condition publicly themselves.

Questions people often ask

Will Graves’ disease go away?
Sometimes. Around half of people stay well after a 12 to 18 month course of tablets, and relapse usually leads to a discussion about radioactive iodine or surgery [4].

Will I need medicine for the rest of my life?
Many people do: almost everyone who has radioactive iodine, and everyone who has the thyroid removed, needs levothyroxine for life [1,4].

My blood tests are normal, so why are my eyes still bad?
Thyroid eye disease follows its own course, unrelated to the severity of the overactive thyroid, and needs its own treatment from an eye doctor [3,11].

Does smoking really make that much difference?
Yes. It raises the chance of developing Graves’ disease, lowers the chance of remission, and is strongly linked with more severe eye disease [4,5,7].

Can I have a baby?
Yes, with planning. Treatment is adjusted before conception: propylthiouracil is preferred when trying to conceive, and radioactive iodine means waiting at least 6 months [8,14].

Sources

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Graves’ Disease. Last reviewed November 2021. https://www.niddk.nih.gov/health-information/endocrine-diseases/graves-disease Accessed 3 August 2026.
  2. NHS. Overactive thyroid (hyperthyroidism): Overview. Page last reviewed 11 April 2023. https://www.nhs.uk/conditions/overactive-thyroid-hyperthyroidism/ Accessed 3 August 2026.
  3. American Thyroid Association. Graves’ Disease (patient information). https://www.thyroid.org/graves-disease/ Accessed 3 August 2026.
  4. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. European Thyroid Journal. 2018;7(4):167-186. doi:10.1159/000490384. https://pmc.ncbi.nlm.nih.gov/articles/PMC6140607/ Accessed 3 August 2026.
  5. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. European Journal of Endocrinology. 2021;185(4):G43-G67. doi:10.1530/EJE-21-0479. Full text read as the open-access PDF at https://www.saedyn.es/wp-content/uploads/2024/02/The-2021-European-Group-on-Graves-orbitopathy-EUGOGO.pdf Accessed 3 August 2026.
  6. Bartalena L, Gallo D, Kahaly GJ, Marinò M, Tanda ML. Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy. European Thyroid Journal. 2025;14(6):e250318. doi:10.1530/ETJ-25-0318. https://pmc.ncbi.nlm.nih.gov/articles/PMC12687763/ Accessed 3 August 2026.
  7. British Thyroid Foundation. Hyperthyroidism. Revised 2018. https://www.btf-thyroid.org/hyperthyroidism-leaflet Accessed 3 August 2026.
  8. NHS. Overactive thyroid (hyperthyroidism): Treatment. Page last reviewed 11 April 2023. https://www.nhs.uk/conditions/overactive-thyroid-hyperthyroidism/treatment/ Accessed 3 August 2026.
  9. NHS. Overactive thyroid (hyperthyroidism): Complications. Page last reviewed 11 April 2023. https://www.nhs.uk/conditions/overactive-thyroid-hyperthyroidism/complications/ Accessed 3 August 2026.
  10. Amgen UK. Amgen’s TEPEZZA (teprotumumab) granted marketing authorisation as the first targeted treatment specifically for adults with moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom. News release, 12 May 2025. https://www.amgen.co.uk/media/news-release/2025/05/amgens-tepezza-teprotumumab-granted-marketing-authorisation-as-the-first-targeted-treatment-specifically-for-adults-with-moderate-to-severe-thyroid-eye-disease-ted-in-the-United-Kingdom Accessed 3 August 2026.
  11. European Medicines Agency. Tepezza (teprotumumab): medicine overview. Marketing authorisation valid throughout the EU on 19 June 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/tepezza Accessed 3 August 2026.
  12. National Institute for Health and Care Excellence (NICE). Teprotumumab for treating thyroid eye disease [ID6432]: project information. Status deferred, 18 March 2026. https://www.nice.org.uk/guidance/indevelopment/gid-ta11531 Accessed 3 August 2026.
  13. European Medicines Agency. First treatment against severe thyroid eye disease. News, 25 April 2025. https://www.ema.europa.eu/en/news/first-treatment-against-severe-thyroid-eye-disease Accessed 3 August 2026.
  14. Dorris K. American Thyroid Association Releases New Guidelines on Thyroid Disease in Pregnancy. Graves’ Disease and Thyroid Foundation, 6 July 2026. https://www.gdatf.org/american-thyroid-association-releases-new-guidelines-on-thyroid-disease-in-pregnancy/ Accessed 3 August 2026.
  15. Graves’ Disease and Thyroid Foundation. Home page and resources. https://www.gdatf.org/ Accessed 3 August 2026.
  16. Viridian Therapeutics. Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease. News release, 26 June 2026. https://s203.q4cdn.com/807813999/files/doc_news/Viridian-Therapeutics-Announces-U-S–FDA-Approval-and-Launch-of-Lumvoa-veligrotug-vvze-for-the-Treatment-of-Thyroid-Eye-Disease-2026.pdf Accessed 3 August 2026.
  17. Thyroid Eye Disease Charitable Trust (TEDct). https://tedct.org.uk/ Accessed 3 August 2026.
  18. Australian Thyroid Foundation. https://www.thyroidfoundation.org.au/ Accessed 3 August 2026.
  19. Prevent Blindness. Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease. 28 June 2021. https://advocacy.preventblindness.org/focus-on-thyroid-eye-disease/ Accessed 3 August 2026.
  20. American Thyroid Association. ATA Guidelines & Statements, listing Korevaar TIM, Leung AM, Alexander EK, et al. American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum. Thyroid. 2026;36(5):481-544, and Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and other causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. https://www.thyroid.org/professionals/ata-professional-guidelines/ Accessed 3 August 2026.

Review information

Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026